Is retatrutide the same as tirzepatide?

No. Tirzepatide is a dual GIP/GLP-1 agonist; retatrutide adds glucagon-receptor activity, making it a triple agonist.

Is retatrutide approved anywhere?

No. Retatrutide has not been approved by any regulator worldwide and remains investigational, despite the pivotal Phase 3 trials having reported positively during 2026.

What does LY3437943 mean?

It is Eli Lilly's internal development code for retatrutide, used in trial registrations and published research.

What Is Retatrutide? LY3437943 and Its Three Receptors

The short answer

Retatrutide (LY3437943) is an investigational triple-receptor agonist peptide developed by Eli Lilly. It binds and activates the GIP, GLP-1, and glucagon receptors simultaneously, making it the first triple-agonist incretin currently progressing through the Phase 3 TRIUMPH clinical trial programme.

Key facts

Chemical name: LY3437943 (Retatrutide)
Class: Triple receptor agonist (GIP/GLP-1/Glucagon)
Molecular weight: ~4,731 Da
Developer: Eli Lilly and Company
Status: Investigational, pivotal Phase 3 reported
Approval: Not approved by FDA, EMA, or MHRA
TRIUMPH-1: 28.3% mean reduction at 80 wks (May 2026)

What is retatrutide chemically?

Retatrutide is a 39-amino-acid synthetic peptide analogue derived from the GIP scaffold, engineered with fatty-acid conjugation to extend its plasma half-life. It is a single-molecule triple agonist: one peptide chain that binds three distinct incretin family receptors at physiologically relevant concentrations.

Who developed retatrutide?

Retatrutide is being developed by Eli Lilly and Company under the internal code LY3437943. The programme sits alongside Lilly's earlier incretin work on dulaglutide (Trulicity) and tirzepatide (Mounjaro / Zepbound), and represents the next generation beyond dual GIP/GLP-1 agonism.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £49.99

What is its regulatory status?

Retatrutide is an investigational compound. It has not received marketing authorisation from the FDA, EMA or MHRA and is available only within clinical-trial and research settings. The pivotal Phase 3 trials have now reported (TRIUMPH-1 in May 2026, TRIUMPH-2 and -3 in July 2026), and Eli Lilly has signalled an intended FDA filing in the first quarter of 2027.

Why is it studied?

Phase 2 data in the New England Journal of Medicine (Jastreboff et al., 2023) reported the largest weight reductions then observed for any single-molecule incretin agonist. The Phase 3 programme has since reinforced that position: TRIUMPH-1 reported mean reduction of 28.3% at 80 weeks on its highest dose arm. This has made retatrutide one of the most widely referenced compounds in current metabolic pharmacology literature.

Frequently asked questions

Is retatrutide the same as tirzepatide?: No. Tirzepatide is a dual GIP/GLP-1 agonist; retatrutide adds glucagon-receptor activity, making it a triple agonist.
Is retatrutide approved anywhere?: No. Retatrutide has not been approved by any regulator worldwide and remains investigational, despite the pivotal Phase 3 trials having reported positively during 2026.
What does LY3437943 mean?: It is Eli Lilly's internal development code for retatrutide, used in trial registrations and published research.

Extended research context

The Retatrutide Research deep dive

Deep dive: how the triple-agonist scaffold was engineered

Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance. This is the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.

The TRIUMPH Phase 3 programme in context

TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator (FDA, EMA, or MHRA) has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.

How retatrutide differs from tirzepatide and semaglutide at the mechanism level

Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press, but the pharmacology is more nuanced than the label implies.

Research applications

▸In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
▸Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
▸Analytical-method development: HPLC retention profiling and LC-MS confirmation
▸Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
▸Reference material for teaching incretin pharmacology in university-level courses

Handling checklist

✓Store lyophilised vials at −20 °C; protect from light and humidity
✓Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
✓Once reconstituted, store at 2–8 °C and use within 28 days
✓Verify batch CoA: HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
✓Do not administer to humans or animals. Research use only

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing retatrutide with tirzepatide in supplier catalogues

Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.

✗ Using tap or filtered water for reconstitution

Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water, never lab DI water.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

What Is Retatrutide? LY3437943, and What a Triple Agonist Does